Dec 20, 2023 | Press Release
CARY, N.C., Dec. 20, 2023 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by Novartis as a specialty pharmacy provider for FABHALTA® (iptacopan). FABHALTA, approved by the U.S. Food and Drug...
Dec 5, 2023 | Press Release
CARY, N.C., Dec.5, 2023—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease, was selected by SpringWorks Therapeutics as a limited distribution specialty pharmacy for OGSIVEO™ (nirogacestat), which is a gamma secretase...
Dec 1, 2023 | Press Release
CARY, N.C., Dec.1, 2023—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by AstraZeneca as a specialty pharmacy provider for TRUQAP™ (capivasertib). TRUQAP, which was approved by the U.S. Food and Drug...
Nov 15, 2023 | News, Press Release
CARY, N.C., Nov. 15, 2023—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by Takeda as a specialty pharmacy provider for FRUZAQLATM (fruquintinib). FRUZAQLA, approved by the U.S. Food and Drug...
Sep 20, 2023 | Press Release
CARY, N.C., Sept. 20, 2023—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by GSK as a specialty pharmacy provider for OJJAARA™ (momelotinib). OJJAARA, approved by the U.S. Food and Drug Administration...
Aug 4, 2023 | Press Release
CARY, N.C., Aug. 4, 2023 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by Daiichi Sankyo, Inc., as a specialty pharmacy provider for VANFLYTA® (quizartinib). VANFLYTA is indicated for use in...